Thus, nivolumab has approved by the FDA as a monotherapy for advanced ESCC patients after prior standard chemotherapy regardless of PD-L1 expression (Yamamoto and Kato, 2020). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.